Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16010033 | 0.88 | ALDH1A1 (0.38) | ALDH1A1LMNAHPGDMAPTSTAT3 | |
| SCHEMBL27755373 | 0.87 | ALDH1A1 (0.41) | ALDH1A1LMNAHPGDMAPTSTAT3 | |
| SCHEMBL17385939 | 0.85 | ALDH1A1 (0.40) | ALDH1A1LMNAHPGDMAPTSTAT3 | |
| SCHEMBL17385919 | 0.84 | ALDH1A1 (0.39) | ALDH1A1LMNAHPGDMAPTSTAT3 | |
| SCHEMBL19616974 | 0.82 | GRM5 (0.33) | ALDH1A1LMNAHPGDMAPTGRM5 | |
| SCHEMBL8420025 | 0.81 | ALDH1A1 (0.45) | ALDH1A1LMNAHPGDMAPTSTAT3 | |
| SCHEMBL14514638 | 0.80 | MAPT (0.41) | ALDH1A1LMNAMAPTSMN1; SMN2PTPN1 | |
| SCHEMBL16515501 | 0.79 | ALDH1A1 (0.44) | ALDH1A1LMNAHPGDMAPTSTAT3 | |
| SCHEMBL31618520 | 0.79 | SMN1; SMN2 (0.31) | ALDH1A1LMNAMAPTSMN1; SMN2ROR1 | |
| SCHEMBL2947790 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTMAPK1GRM5ROR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2743268-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2248812-B1 | FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8598226-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-03 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-10-10 | — | — | US | disclosed |
| US-8492430-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2041123-A2 | FUSED CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | ALDH1A1 3122/4885LMNA 4399/4885HPGD 1390/4885 |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | ALDH1A1 3122/4885LMNA 4399/4885HPGD 1390/4885 |
| US-20130267589-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | ALDH1A1 3122/4885LMNA 4399/4885HPGD 1390/4885 |
| US-20100197761-A1 | Fused cyclic compounds | GPR119, GLP1R, GPR65 | ALDH1A1 3122/4885LMNA 4399/4885HPGD 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.